We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other stocks. Ten ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...
Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...
InDevR partners with Aldevron to describe how the VaxArray 5′CapQ assay can be used to measure intact mRNA in a single assay to streamline bioprocess development.
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...
For decades, scientists have tried to stop cancer by disabling the mutated proteins that are found in tumors. But many cancers manage to overcome this and continue growing. Now, scientists think they ...
TriLink BioTechnologies, a Maravai LifeSciences (MRVI) company and global provider of life science reagents and services, has signed a ...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on regulatory guidance for ...
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
Goldman has recently reduced Moderna Inc (MRNA) stock to Neutral rating, as announced on January 29, 2025, according to Finviz. Earlier, on December 18, 2024, Argus had reduced the stock from a Buy to ...
The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback